1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

The Greatest FDA Advisory Committees, Part III: The Power of The Patients

 
• By Ramsey Baghdadi

With landmark advisory committee meetings coming up, we take a look back at some of the memorable panel meetings over the last 20 years.

Microphone at a meeting
The open public hearing can sometimes change the tenor of an advisory committee. • Source: Shutterstock

The upcoming advisory committee reviews of the first coronavirus vaccine(s) and Biogen, Inc.’s aducanumab for Alzheimer’s should be two historic panel meetings, prompting a look back at the greatest FDA advisory committees of the last 20 years. (Here are Part I and Part II.)

In Part III of the series, we look at an advisory committee review from 2010: Benlysta. Human Genome Sciences, Inc./GlaxoSmithKline plc’s Benlysta (belimumab) for lupus was notable for several reasons

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers